Replies to post #106918 on Avid Bioservices Inc (CDMO)

[eddiebali]

Fda are a strange bunch. Their decisions have sometimes shocked.Fingers crossed

[pphmtoolong]

Right on brother mojojojo! Or is that sister mojojojo? If the front line NSCLC trial MOS is 50-75% better than the SOC, and the same holds true from the Pancreatic cancer trial, I don't see any way this stock stays below $5. As we all know these two trials must be nearing positive MOS announcements. At this point it seems that the only question is how much Bavi MOS improves on the SOC in these deadly diseases.

Sitting tight, enjoying the show.

Paul